Piper Jaffray analyst Sean Wieland is "incrementally more positive" on Tabula Rasa HealthCare's (TRHC) growth outlook after traveling with the company's CFO Brian Adams. CVS Health (CVS) provides a "strong validation" of Tabula Rasa's value proposition, and multiple opportunities should result in a higher margin product mix, Wieland tells investors in a research note. Further, the analyst believes the recent weakness in the stock has created a "compelling entry point." He reiterates an Overweight rating on Tabula Rasa HealthCare with a $73 price target.